Everything for Your Home's
Beauty, Comfort & Convenience 384-2123
704 Jamestown St, Columbia
Dr. Ronald P. Rogers
Support for your body's natural healing capabilities
Click here for details
Click here for information
Real Estate & Auction Co.
Duo County Telecom
Now Available Through
Your Cable Service!
GUN & PAWN
What's Going On
Info about the
Janice Holt Giles
and Henry Giles Society
Columbia Gas Dept.
GAS LEAK or GAS SMELL
24 hrs/ 365 days
270-384-2006 or 9-1-1
Call before you dig
Directory of Churches
phone numbers and more
for churches in Adair County
Beshear: Reformulated painkiller still subject to abuse
Kentucky Attorney General Andy Beshear says opioid painkiller being pulled by pharmaceutical company is just a 'First Step' in fighting epidemic.
By Terry Sebastian, Crystal Staley
Frankfort, KY - In 2015, more than 225 Kentuckians died from a drug overdose with Opana in their blood.
Now that the makers of the opioid painkiller announced July 6 that it will no longer sell the drug, Attorney General Andy Beshear is calling the move a "first step" in fighting against what he believes is the single greatest threat to Kentucky - the state's drug epidemic.
Beshear sent his concerns on the potential for abuse by Kentuckians on a reformulation of the drug, Opana ER (extended release), to the U.S. Food and Drug Administration (FDA) in February during an open comment period on the drug.
"The FDA previously determined the reformulated Opana ER can still be readily prepared for injection and can be crushed with common items for snorting," Beshear said in his comments to the agency. "'Snortable' or injectable drugs have crippled Kentucky, ranging from the widespread abuse of Oxycontin to the return of heroin. Where the reformulation has merely been found to impede one of many means of abuse, approving labeling Opana ER as 'abuse deterrent' may mislead patients and providers."
In his comments, Beshear said he was "encouraged that the agency is taking a hard look at the safety of this powerful drug."
The FDA requested on June 8 that Endo Pharmaceuticals remove Opana ER from the market.
Beshear's comments to the FDA on Opana ER is part of his ongoing efforts to address the opioid crisis in Kentucky.
"Opana ER has already taken the lives of Kentuckians," Beshear said. "Louisvillian Emily Walden, whose son, T.J., died of an Opana ER overdose in 2012, has led the charge to have the reformulated drug removed from the market. By working hand-in-hand with dedicated Kentuckians like Emily, we can and will end our opioid epidemic."
On June 28, Beshear announced that his office intends to file multiple lawsuits against drug manufacturers, distributors and retailers where there is evidence that they contributed to the opioid epidemic by illegally marketing and selling opioids to Kentuckians.
To support this litigation, Beshear issued a request for proposal (RFP) for legal services to assist the Commonwealth in multiple lawsuits and to ensure that Kentucky tax dollars are not used for the costs of the litigations.
Beshear is co-chair on the National Association of Attorneys General Substance Abuse Committee.
The AG's office previously settled a $24 million lawsuit with Purdue Pharma regarding OxyContin. Beshear's office has provided $8 million from that settlement directly to 15 substance treatment centers across Kentucky.
From a different drug company settlement, the office dedicated $2 million to expand and enhance Rocket Docket programs that expedite drug cases, generate significant cost savings and allow select defendants rapid access to substance abuse treatment.
Recently, Beshear joined a multistate lawsuit alleging the drugmaker of Suboxone, a drug used for treating opioid addiction, tried to monopolize the market.
Beshear is currently working with local law enforcement and community leaders to host substance abuse awareness forums across the state. The office has also been instrumental in numerous drug related arrests, including working with federal authorities on arresting a fentanyl dealer whose drugs had killed several Kentuckians.
"The abuse and diversion of Opana and other strong opioids is devastating the health of many of our Commonwealth's citizens, and they, as well as our Medicaid and corrections departments, pay an enormous financial price in the attempt to treat this epidemic," Beshear told the FDA. "It would benefit public health for the FDA to create and implement deadlines for the pharmaceutical industry to develop more robust abuse deterrent formulations for these high-dose opioids and to require that development before granting abuse deterrent labeling."
This story was posted on 2017-07-08 06:41:55
Printable: this page is now automatically formatted for printing.
Have comments or corrections for this story? Use our contact form and let us know.
To sponsor news and features on ColumbiaMagazine, please use our contact form.
More articles from topic Kentucky:
I-65 interchange & connector opened today in Warren Co., KY
Gov. Bevin Makes appointments to KY Commissions, Board
AG returns nearly $8 million to General Fund
Adair, Taylor, Russell show growth in latest estimates
Bluegrass Supply Chain Services to add location in Park City, KY
Kentucky AG reaches settlement with Louisville based HVAC Co
Louisville, KY man sentenced to 97 months
Tornadoes struck 23 Jun 2017 LaRue, Marion Counties, KY
Kentucky selected to host 2019 NCSLA Annual Conference
Lodge at Jenny Wiley reopens
View even more articles in topic Kentucky
Click for Info
Bank of Columbia
If You're Thinking of Selling,
Let Us Do the Yelling
Principal Broker & Auctioneer
Burton Real Estate
& Auction Service
Call Us For Appraisals
Click for Listings
On This Site
or Click Here
The Best of
Local Stories of
The Greatest Generation
Order Book or e-Book
See who's celebrating
Birthdays and Anniversaries
Special Events List
Find Great Stuff in
Antiques, Help Wanted,
Autos, Real Estate,
Legal Notices, More...
ColumbiaMagazine.com content is available as an RSS/XML feed for your RSS reader or other news aggregator.
Contact us: Columbia Magazine and columbiamagazine.com are published by D'Zine, Ltd., PO Box 906, Columbia, KY 42728.